• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

MOTESANIB Drug Record

  • Summary
  • Interactions
  • Claims
  • MOTESANIB chembl:CHEMBL572881 Antineoplastic

    Alternate Names:

    AMG-706
    MOTESANIB
    AMG 706
    N-(2,3-DIHYDRO-3,3-DIMETHYL-1H-INDOL-6-YL)-2-((4-PYRIDINYLMETHYL)AMINO)-3-PYRIDINECARBOXAMIDE
    pubchem.compound:11667893
    chembl:CHEMBL572881
    drugbank:05575
    chemidplus:453562-69-1

    Drug Info:

    FDA Approval not approved
    Drug Class Small molecule
    Drug Indications antineoplastic agent
    Drug Class Kinase Inhibitors
    (5 More Sources)

    Publications:

    Maitland ML et al., 2010, Vascular endothelial growth factor pathway., Pharmacogenet Genomics
    Coxon et al., 2012, Anti-tumor activity of motesanib in a medullary thyroid cancer model., J. Endocrinol. Invest.
    Caenepeel et al., 2010, Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors., J. Exp. Clin. Cancer Res.
  • MOTESANIB   KIT

    Interaction Score: 0.76

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Stem cell growth factor receptor inhibitor
    Direct Interaction yes
    Notes

    PMIDs:
    20633291


    Sources:
    TALC MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions

  • MOTESANIB   RET

    Interaction Score: 0.75

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical - Cell line xenograft
    Response Type predicted – sensitive

    PMIDs:
    21422803


    Sources:
    TALC MyCancerGenome JAX-CKB ChemblInteractions CIViC

  • MOTESANIB   FLT1

    Interaction Score: 0.58

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    Trial Name motesanib diphosphate, AMG 706
    Novel drug target Established target

    PMIDs:
    20124951


    Sources:
    TALC MyCancerGenome TdgClinicalTrial ChemblInteractions PharmGKB

  • MOTESANIB   KDR

    Interaction Score: 0.49

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Vascular endothelial growth factor receptor inhibitor
    Direct Interaction yes
    Trial Name motesanib diphosphate, AMG 706

    PMIDs:
    20124951 21422803


    Sources:
    TALC MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions PharmGKB

  • MOTESANIB   PDGFRB

    Interaction Score: 0.44

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    Novel drug target Established target
    Trial Name motesanib diphosphate, AMG 706

    PMIDs:
    None found


    Sources:
    TALC MyCancerGenome TdgClinicalTrial ChemblInteractions

  • MOTESANIB   FLT4

    Interaction Score: 0.37

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Vascular endothelial growth factor receptor inhibitor
    Direct Interaction yes
    Notes

    PMIDs:
    None found


    Sources:
    TALC MyCancerGenome TdgClinicalTrial ChemblInteractions

  • MOTESANIB   PDGFRA

    Interaction Score: 0.36

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Platelet-derived growth factor receptor inhibitor
    Direct Interaction yes
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    MyCancerGenome TdgClinicalTrial ChemblInteractions

  • MOTESANIB   YES1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • MyCancerGenome: MOTESANIB

    • Version: 20-Jun-2017

    Alternate Names:
    MOTESANIB Generic Name

    Drug Info:
    Drug Class Kinase Inhibitors

    Publications:

  • TdgClinicalTrial: MOTESANIB

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent
    Drug Class Small molecule
    FDA Approval not approved

    Publications:

  • JAX-CKB: Motesanib

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Caenepeel et al., 2010, Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors., J. Exp. Clin. Cancer Res.
    Coxon et al., 2012, Anti-tumor activity of motesanib in a medullary thyroid cancer model., J. Endocrinol. Invest.

  • PharmGKB: motesanib

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Maitland ML et al., 2010, Vascular endothelial growth factor pathway., Pharmacogenet Genomics

  • CIViC: MOTESANIB

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Coxon et al., 2012, Anti-tumor activity of motesanib in a medullary thyroid cancer model., J. Endocrinol. Invest.

  • TALC: MOTESANIB

    • Version: 12-May-2016

    Alternate Names:
    MOTESANIB Primary Drug Name
    MOTESANIB Drug Generic Name

    Drug Info:

    Publications:

  • DTC: MOTESANIB

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL572881 ChEMBL Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL572881

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL572881

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21